Phase i dendritic cell p53 peptide vaccine for head and neck cancer

Clinical Cancer Research

Volumn 20, Issue 9, 2014, Pages 2433-2444

  Schuler, Patrick J ^a,d   Harasymczuk, Malgorzata ^a   Visus, Carmen ^b   De Leo, Albert ^b   Trivedi, Sumita ^a,b   Lei, Yu ^a   Argiris, Athanassios ^c   Gooding, William ^a   Butterfield, Lisa H ^b   Whiteside, Theresa L ^a,b   Ferris, Robert L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; PROTEIN P53; TETANUS TOXOID; CANCER VACCINE; CYTOKINE; PEPTIDE FRAGMENT;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; INGUINAL LYMPH NODE; MIDDLE AGED; MONOCYTE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; WILD TYPE; ADVERSE EFFECTS; BIOSYNTHESIS; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; CHEMISTRY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; GENETICS; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; METABOLISM; MORTALITY; PATHOLOGY; PHENOTYPE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; VACCINATION;

ADULT; AGED; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; CYTOKINES; DENDRITIC CELLS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOPLASM STAGING; PEPTIDE FRAGMENTS; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; VACCINATION;

EID: 84899728764     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2617     Document Type: Article

References (44)

1. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008;371:1695-709.
2. Shurin MR, Shurin GV, Lokshin A, Yurkovetsky ZR, Gutkin DW, Chatta G, et al. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 2006;25:333-56.
3. Whiteside TL, Stanson J, Shurin MR, Ferrone S. Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol 2004;173:1526-34.
4. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 2006;12:3890-5.
5. Strauss L, Bergmann C, Whiteside TL. Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer 2007;121: 2473-83.
6. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev 1999;170:85-100.
7. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-60.
8. Sirianni N, Ha PK, Oelke M, Califano J, Gooding W, Westra W, et al. Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10:6929-37.
9. Petersen TR, Buus S, Brunak S, Nissen MH, Sherman LA, Claesson MH. Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity. Scand J Immunol 2001;53: 357-64.
10. Andrade FilhoPA, Ito D, Deleo AB, Ferris RL.CD8+T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2010;59:1561-8.
11. Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet JG, Choppin J. Accumulation of the p53 protein allows recognition by human CTL of a wildtype p53 epitope presented by breast carcinomas and melanomas. J Immunol 1998;160:328-33.
12. Albers AE, Ferris RL, Kim GG, Chikamatsu K, DeLeo AB, Whiteside TL. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother 2005;54:1072-81.
13. Hoffmann TK, Donnenberg AD, Finkelstein SD, Donnenberg VS, Friebe-Hoffmann U, Myers EN, et al. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res 2002;62:3521-9.
14. Hoffmann TK, Nakano K, Elder EM, Dworacki G, Finkelstein SD, Appella E, et al. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol 2000;165: 5938-44.
15. Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother 2012;61:373-84.
16. DeLeo AB, Whiteside TL. Development of multi-epitope vaccines targeting wild-type sequence p53 peptides. Expert Rev Vaccines 2008;7:1031-40.
17. Chikamatsu K, Albers A, Stanson J, Kwok WW, Appella E, Whiteside TL, et al. P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res 2003;63:3675-81.
18. Slingluff CL Jr, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, et al. Phase I trial of a melanoma vaccine with gp100 (280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 2001;7:3012-24.
19. Hoffmann TK, Loftus DJ, Nakano K, Maeurer MJ, Chikamatsu K, Appella E, et al. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope. J Immunol 2002;168:1338-47.
20. Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, et al. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol 2003;171:2366-73.
21. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004;64:5934-7.
22. Hoffmann TK, Meidenbauer N, Muller-Berghaus J, Storkus WJ, Whiteside TL. Proinflammatory cytokines and CD40 ligand enhance crosspresentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells. J Immunother 2001;24:162-71.
23. Valmori D, Pessi A, Bianchi E, Corradin G. Use of human universally antigenic tetanus toxin T-cell epitopes as carriers for human vaccination. J Immunol 1992;149:717-21.
24. Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016-26.
25. Demotz S, Lanzavecchia A, Eisel U, Niemann H, Widmann C, Corradin G. Delineation of several Dr-restricted tetanus toxin T-cell epitopes. J Immunol 1989;142:394-402.
26. Visus C, Ito D, Amoscato A, Maciejewska-Franczak M, Abdelsalem A, Dhir R, et al. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res 2007;67: 10538-45.
27. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011;29:330-6.
28. Schuler PJ, Schilling B, Harasymczuk M, Hoffmann TK, Johnson J, Lang S, et al. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur J Immunol 2012;42:1876-85.
29. Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 2000;60:3542-9.
30. Lopez-Albaitero A, Mailliard R, Hackman T, Andrade Filho PA, Wang X, Gooding W, et al. Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function. J Immunother 2009;32:465-73.
31. Lopez-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006;176:3402-9.
32. Argiris A, Heron DE, Smith RP, Kim S, Gibson MK, Lai SY, et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol 2010;28:5294-300.
33. Schuler PJ, Harasymczuk M, Schilling B, Lang S, Whiteside TL. Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Methods 2011;369:59-68.
34. Amigorena S, Savina A. Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr Opin Immunol 2010;22:109-17.
35. Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 2010; 15:994-1001.
36. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-52.
37. Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in highrisk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2012;84:1198-205.
38. Ferris RL, Kotsakis AP, Heron DE, Kim S, Duvvuri U, Kubicek GJ, et al. A phase II trial of postoperative radiotherapy (RT), cisplatin, and panitumumab in patients with high-risk, resected locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 28:15s, 2010 (suppl; abstr TPS262).
39. Ferrone S, Whiteside TL. Tumor microenvironment and immune escape. Surg Oncol Clin N Am 2007;16:755-74.
40. Bergmann C, Strauss L, Wang Y, Szczepanski MJ, Lang S, Johnson JT, et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 2008;14:3706-15.
41. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007;67:8865-73.
42. Balz V, Scheckenbach K, Gotte K, Bockmuhl U, Petersen I, Bier H. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 2003;63:1188-91.
43. Nijman HW, Lambeck A, van der Burg SH, van der Zee AG, Daemen T. Immunologic aspect of ovarian cancer and p53 as tumor antigen. J Transl Med 2005;3:34.
44. Svane IM, Pedersen AE, Johansen JS, Johnsen HE, Nielsen D, Kamby C, et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother 2007;56: 1485-99.